Dravet syndrome (DS) is a severe, drug-resistant epilepsy. Fenfluramine has been reported to have a long-term clinically meaningful anticonvulsive effect in patients with DS.status: publishe
Fenfluramine hydrochloride has classically been described as acting pharmacologically through a sero...
IntroductionFenfluramine (FFA) is an amphetamine derivative that promotes the release and blocks the...
BackgroundDravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized ...
In this paper, we review the experience with fenfluramine in epileptic and other paroxysmal disorder...
BACKGROUND: Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopathy ch...
Importance: Fenfluramine treatment may reduce monthly convulsive seizure frequency in patients with ...
A 20-year-old woman with Dravet syndrome and multiple prior episodes of status epilepticus presented...
Objective: Dravet syndrome (DS) is a rare but severe drug-resistant epilepsy. Before the approval of...
Objective: To examine the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS...
Dravet Syndrome is a severe, drug-resistant, and rare epileptiform disorder that is typically presen...
Introduction: Dravet syndrome (DS), a prototypic developmental and genetic epileptic encephalopathy ...
AbstractAn adult woman with Dravet syndrome (documented SCN1A mutation) experienced a marked reducti...
An adult woman with Dravet syndrome (documented SCN1A mutation) experienced a marked reduction in se...
Introduction: Dravet syndrome (DS) is an early-onset genetic developmental epileptic encephalopathy ...
Fenfluramine, tradename Fintepla ®, was appraised within the National Institute for Health and Care ...
Fenfluramine hydrochloride has classically been described as acting pharmacologically through a sero...
IntroductionFenfluramine (FFA) is an amphetamine derivative that promotes the release and blocks the...
BackgroundDravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized ...
In this paper, we review the experience with fenfluramine in epileptic and other paroxysmal disorder...
BACKGROUND: Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopathy ch...
Importance: Fenfluramine treatment may reduce monthly convulsive seizure frequency in patients with ...
A 20-year-old woman with Dravet syndrome and multiple prior episodes of status epilepticus presented...
Objective: Dravet syndrome (DS) is a rare but severe drug-resistant epilepsy. Before the approval of...
Objective: To examine the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS...
Dravet Syndrome is a severe, drug-resistant, and rare epileptiform disorder that is typically presen...
Introduction: Dravet syndrome (DS), a prototypic developmental and genetic epileptic encephalopathy ...
AbstractAn adult woman with Dravet syndrome (documented SCN1A mutation) experienced a marked reducti...
An adult woman with Dravet syndrome (documented SCN1A mutation) experienced a marked reduction in se...
Introduction: Dravet syndrome (DS) is an early-onset genetic developmental epileptic encephalopathy ...
Fenfluramine, tradename Fintepla ®, was appraised within the National Institute for Health and Care ...
Fenfluramine hydrochloride has classically been described as acting pharmacologically through a sero...
IntroductionFenfluramine (FFA) is an amphetamine derivative that promotes the release and blocks the...
BackgroundDravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized ...